Genesis Therapeutics

Technical Program Manager, Foundation Models (Staff / Principal)

New York, New York, United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Artificial Intelligence, Drug DiscoveryIndustries

Requirements

Candidates must be a seasoned Technical Program Manager with significant experience managing complex ML, scientific computing, or biotech-focused projects. A deeply technical background allowing fluent communication with ML researchers, platform engineers, and computational chemists is essential. Expertise in navigating research-driven ambiguity, bringing structure to open-ended scientific projects, and aligning priorities across science and engineering is required. Candidates must be masters of execution and organization, able to translate high-level strategy into detailed plans and manage multiple concurrent workstreams flawlessly. Exceptional communication and collaboration skills, excelling at building consensus and aligning technical and non-technical partners toward a common goal, are necessary. Passion for advancing science through technology in high-impact, mission-driven work is a must. A BS or higher in Computer Science, Computational Chemistry, BioEngineering, or a related field is a plus.

Responsibilities

The Technical Program Manager will orchestrate the end-to-end delivery of foundation models, translating strategic research goals into executable roadmaps and concrete milestones. They will manage large-scale compute resources, partnering with research and engineering leads to ensure efficient scheduling and allocation for critical experiments. Responsibilities include implementing and overseeing configuration management to ensure research is reproducible, traceable, and robust. The role involves driving cross-functional execution and mitigating risk by proactively identifying dependencies, anticipating blockers, and ensuring clear communication across all teams. Additionally, they will design and mature operational processes, creating effective systems for experiment tracking, project documentation, and model release governance, and act as a central communication hub for stakeholders.

Skills

Technical Program Management
Foundation Models
AI
Machine Learning
Deep Learning
Drug Discovery
Scientific Initiatives
Engineering Initiatives
Research Roadmap
Generative Models
Large-scale Simulations
Compute Resources
Configuration Management
Model Deployment
Program Management
Experiment Governance
Platform Engineering

Genesis Therapeutics

AI-driven drug discovery for pharmaceuticals

About Genesis Therapeutics

Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis Therapeutics focuses on strategic partnerships with other biotech and pharmaceutical companies, generating revenue through upfront payments and future earnings based on drug success. The goal is to transform the drug discovery process and bring new therapies to market.

Burlingame, CaliforniaHeadquarters
2019Year Founded
$272.5MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees

Benefits

Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program

Risks

Competition from AI-driven companies like Insilico Medicine and Exscientia is increasing.
Over-reliance on partnerships could lead to financial instability if drugs aren't successful.
Rapid AI advancements may render current models like GEMS obsolete without updates.

Differentiation

Genesis Therapeutics uses AI to accelerate drug discovery with 3D spatial graph modeling.
The GEMS platform integrates deep learning, molecular simulations, and generative AI for drug design.
Strategic partnerships with Eli Lilly and Gilead highlight Genesis' industry collaboration strength.

Upsides

Partnership with NVIDIA enhances GEMS platform for targeting undruggable diseases.
$224 million equity investment boosts research and development capabilities.
Recognition as a 'Fierce 15' company underscores AI's role in breakthrough therapeutics.

Land your dream remote job 3x faster with AI